European Access Academy
A multi-stakeholder initiative aiming to facilitate and support the development of a joint European value framework for the assessment of innovative health technologies
The European Access Academy (EAA) aims to identify key challenges and provide sound input for the implementation of the EU HTA Regulation to help achieve the EC’s mission of improving patient access to life- saving innovative technologies.
The
EAA Faculty is acting as Steering Committee for the EAA's work, providing guidance on strategy, supporting peer-reviewed publications and ensuring scientific integrity. As such, it is listed in the EU Transparency Register and was accepted as a member of the European Commission's HTA Stakeholder Network.
EAA Fall Convention 2026
"A Multi-Stakeholder Glance into the Initial EU HTA Assessments"
jointly hosted by the EAA with European Patients' Forum (EPF)
November 19/20th at INFARMED in Lisbon, Portugal
Join the expert panel on-site or virtually:
Rui Santos Ivo, Marta Temido, Valentina Barbuto, Niklas Hedberg, Valentia Strammiello, Bernhard Wörmann, Alexander Natz, Noémie Manent, Solène Jouan, Robin Doeswijk, Belén Torres Garrido, James Ryan, Mariane Cossito, Dirk Arnold, Tiago Rodrigues, Sara Couto, Martin Scott, Anita Granero, Kleoniki Roka, Susanne Goldbach, Janbernd Kirschner, Merel Hennink, Anne-Marie Dingemans, Ingrid Krücken, Dario Trapani and many more
Adjunct Pre-Convention Meeting
"EU HTA for Medical Devices - Ready to Go?"
jointly hosted by the EAA with MedTech Europe
Join the expert panel incl. Antonieta Lucas, Pedro Moutinho, Ruben Casado-Arroyo, Andrea Rappagliosi, Teresa Barcina Lacosta, and many more, on-site in Lisbon
EAA News & Media Posts
October 12, 2026: Jörg Ruof @ WHS: Key Hypotheses on the "Chronification of Cancer"
At the 2026 World Health Summit in Berlin, Jörg Ruof participated in the BeOne Symposium "Cancer is Changing: Is Care Keeping Pace? When Cancer Becomes a Long-Term Condition". His key hypotheses on this topic are:
1) Chronification of many oncology conditions is a major achievement of the past decades. However, the battle is not over yet; Cancer, different from conditions such as HCV, still remains a life-threatening condition.
2) Europe is transitioning from the Pharma Hub to the HTA Hub of the world. The major concern is that Europe does not any more value innovation, a fear recently voiced by 9 pharma CEOs in an open letter.
3) Health Technology Assessment, and in particular EU HTA, is fully supported by the EAA, but it needs to be slim/ meaningful/ and finally: facilitate rapid access to beneficial medicines for patients in need.
4) Rational Value and Pricing Decisions - which is at the heart of the EU HTA Regulation - are at risk in an environment of global disruptive and intransparent pricing policies such as MFN.
5) Europe has to turn EU HTA into a success story. Key requirements are:
- EU level: consolidation of PICOs (approach the ‚lead PICO era‘ where Europe will consolidate and specify their comparative data needs)
- Member State level: rapid national pull-through i.e., ensure that across the European Union medicines with an additional benefit are rapidly reaching patients in need
- Both Member State and EU level: ensure full involvement of the most knowledgeable patients and clinical experts including their respective scientific societies’ views in the process from beginning to the end.
July 17, 2026: Joint Statement by CPE & EAA on the JCA reports for Lurbinectedin & Tarlatamab
June 18 & 19, 2026: Two days on Health Policy and EU HTA in the global context, organised by the University of Strasbourg
June 16, 2026: Joint Statement by CPE & EAA on the first JCA report (Tovorafenib)
further news and articles can be found in the EAA News Archive
Topical Collection at the Journal of Market Access and Health Policy on EU HTA:
The European Access Academy (EAA) and the Market Access Society (MAS) are editing a Topical Collection at JMAHP focusing on EU HTA, with Jörg Ruof and Mondher Toumi as guest editors. The goal of the Collection is to generate a comprehensive resource consolidating relevant information and diverse perspectives from various stakeholders and a range of focus topics regarding EU HTA.
Access the Collection HERE directly at the journal or find a list of all articles in this collection HERE.
